The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data

[1]  D. Ménard,et al.  Improving Methods for Analyzing Antimalarial Drug Efficacy Trials: Molecular Correction Based on Length-Polymorphic Markers msp-1, msp-2, and glurp , 2019, Antimicrobial Agents and Chemotherapy.

[2]  G. Snounou,et al.  PCR correction strategies for malaria drug trials: updates and clarifications. , 2019, The Lancet. Infectious diseases.

[3]  P. Gething,et al.  Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether–lumefantrine and artesunate–amodiaquine in Africa , 2018, BMJ Global Health.

[4]  R. Grais,et al.  Seasonal malaria chemoprevention: successes and missed opportunities , 2017, Malaria Journal.

[5]  Hannah C. Slater,et al.  Mathematical Modelling to Guide Drug Development for Malaria Elimination , 2017, Trends in parasitology.

[6]  H. Sorgho,et al.  Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso , 2016, Parasite.

[7]  J. Le bras,et al.  Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate–amodiaquine fixed dose combination or artemether–lumefantrine in Liberia , 2016, Malaria Journal.

[8]  Teun Bousema,et al.  Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data , 2016, BMC Medicine.

[9]  WWARN Gametocyte Study Group,et al.  Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data , 2016, BMC Medicine.

[10]  P. Rosenthal,et al.  Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial. , 2016, The Journal of infectious diseases.

[11]  E. Owusu-Dabo,et al.  Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso , 2016, PloS one.

[12]  U. Dalrymple,et al.  The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015 , 2015, Nature.

[13]  F. Nosten,et al.  Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border , 2015, Antimicrobial Agents and Chemotherapy.

[14]  I. Hastings,et al.  Measuring windows of selection for anti-malarial drug treatments , 2015, Malaria Journal.

[15]  M. Pluciński,et al.  Robust Algorithm for Systematic Classification of Malaria Late Treatment Failures as Recrudescence or Reinfection Using Microsatellite Genotyping , 2015, Antimicrobial Agents and Chemotherapy.

[16]  H. Tinto,et al.  Dynamic of plasmodium falciparum chloroquine resistance transporter gene Pfcrt K76T mutation five years after withdrawal of chloroquine in Burkina Faso , 2015, The Pan African medical journal.

[17]  S. Abdulla,et al.  The effect of dose on the antimalarial efficacy of artemether – lumefantrine : a systematic review and pooled analysis of individual patient data Worldwide Antimalarial Resistance Network ( WWARN ) AL Dose Impact Study Group , 2015 .

[18]  C. Sutherland,et al.  Persistence of chloroquine-resistant haplotypes of Plasmodium falciparum in children with uncomplicated Malaria in Lagos, Nigeria, four years after change of chloroquine as first-line antimalarial medicine , 2015, Diagnostic Pathology.

[19]  P. Rosenthal,et al.  Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso , 2015, Antimicrobial Agents and Chemotherapy.

[20]  R. Maude,et al.  Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker , 2015, The Lancet. Infectious diseases.

[21]  Ogobara K. Doumbo,et al.  The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. , 2015 .

[22]  The WorldWide Antimalarial Resistance Network AS-AQ St Group,et al.  The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data , 2015, BMC Medicine.

[23]  J. Gut,et al.  Impact of Antimalarial Treatment and Chemoprevention on the Drug Sensitivity of Malaria Parasites Isolated from Ugandan Children , 2015, Antimicrobial Agents and Chemotherapy.

[24]  M. Kamya,et al.  Efficacy and Safety of Fixed-Dose Artesunate-Amodiaquine vs. Artemether-Lumefantrine for Repeated Treatment of Uncomplicated Malaria in Ugandan Children , 2014, PloS one.

[25]  A. Ghani,et al.  Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis , 2014, Nature Communications.

[26]  A. Sié,et al.  Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults , 2014, Malaria Journal.

[27]  D. P. Mawili-Mboumba,et al.  Pfcrt 76T and pfmdr1 86Y allele frequency in Plasmodium falciparum isolates and use of self-medication in a rural area of Gabon. , 2014, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[28]  Badria B. El-Sayed,et al.  Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for P. falciparum Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine , 2014, The American journal of tropical medicine and hygiene.

[29]  P. Rosenthal,et al.  Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. , 2014, The American journal of tropical medicine and hygiene.

[30]  P. Rosenthal,et al.  Differential prevalence of transporter polymorphisms in symptomatic and asymptomatic falciparum malaria infections in Uganda. , 2014, The Journal of infectious diseases.

[31]  Y. Tozan,et al.  Dihydroartemisinin-Piperaquine vs. Artemether-Lumefantrine for First-Line Treatment of Uncomplicated Malaria in African Children: A Cost-Effectiveness Analysis , 2014, PloS one.

[32]  P. Rosenthal,et al.  Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso , 2014, Antimicrobial Agents and Chemotherapy.

[33]  Neil M. Ferguson,et al.  Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa , 2014, Nature Communications.

[34]  Mehul Dhorda,et al.  Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda , 2013, Antimicrobial Agents and Chemotherapy.

[35]  O. Doumbo,et al.  [Prevalence of Plasmodium falciparum, anemia and molecular markers of chloroquine and sulfadoxine-pyriméthamine resistance in delivered women in Fana, Mali]. , 2013, Bulletin de la Societe de pathologie exotique.

[36]  O. Doumbo,et al.  Prévalence de Plasmodium falciparum, de l’anémie et des marqueurs moléculaires de la résistance à la chloroquine et à la sulfadoxine-pyrim éthamine chez les femmes accouchées à Fana, Mali , 2013 .

[37]  E. Ashley,et al.  Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial , 2013, Malaria Journal.

[38]  P. Rosenthal,et al.  Fitness Consequences of Plasmodium falciparum pfmdr1 Polymorphisms Inferred from Ex Vivo Culture of Ugandan Parasites , 2013, Antimicrobial Agents and Chemotherapy.

[39]  A. Githeko,et al.  Alterations in Plasmodium falciparum genetic structure two years after increased malaria control efforts in western Kenya. , 2013, The American journal of tropical medicine and hygiene.

[40]  F. Nosten,et al.  Population Pharmacokinetic and Pharmacodynamic Modeling of Amodiaquine and Desethylamodiaquine in Women with Plasmodium vivax Malaria during and after Pregnancy , 2012, Antimicrobial Agents and Chemotherapy.

[41]  J. Gaudart,et al.  Repeated Artemisinin-Based Combination Therapies in a Malaria Hyperendemic Area of Mali: Efficacy, Safety, and Public Health Impact , 2012, The American journal of tropical medicine and hygiene.

[42]  P. Guérin,et al.  Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial , 2012, Malaria Journal.

[43]  C. Happi,et al.  In vitro amodiaquine resistance and its association with mutations in pfcrt and pfmdr1 genes of Plasmodium falciparum isolates from Nigeria. , 2011, Acta tropica.

[44]  J. Beeson.  A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial , 2011, PLoS medicine.

[45]  K. Dietz,et al.  A thirteen-year analysis of Plasmodium falciparum populations reveals high conservation of the mutant pfcrt haplotype despite the withdrawal of chloroquine from national treatment guidelines in Gabon , 2011, Malaria Journal.

[46]  Renuka Kunte,et al.  WHO Guidelines for the treatment of malaria , 2011 .

[47]  A. Ghani,et al.  Modelling the Protective Efficacy of Alternative Delivery Schedules for Intermittent Preventive Treatment of Malaria in Infants and Children , 2011, PloS one.

[48]  Yongyuth Yuthavong,et al.  A Research Agenda for Malaria Eradication: Drugs , 2011, PLoS medicine.

[49]  C. Karema,et al.  A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial , 2011 .

[50]  S. Prigge,et al.  Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya , 2010, Malaria Journal.

[51]  O. Ojurongbe,et al.  Molecular surveillance of drug-resistant Plasmodium falciparum in two distinct geographical areas of Nigeria , 2010, Wiener klinische Wochenschrift.

[52]  Wes Hinsley,et al.  Reducing Plasmodium falciparum Malaria Transmission in Africa: A Model-Based Evaluation of Intervention Strategies , 2010, PLoS medicine.

[53]  Daniel Chandramohan,et al.  Intermittent preventive treatment against malaria: an update , 2010, Expert review of anti-infective therapy.

[54]  P. Rosenthal,et al.  Selection of Known Plasmodium falciparum Resistance-Mediating Polymorphisms by Artemether-Lumefantrine and Amodiaquine- Sulfadoxine-Pyrimethamine but Not Dihydroartemisinin- Piperaquine in Burkina Faso , 2010, Antimicrobial Agents and Chemotherapy.

[55]  R. Durand,et al.  Association of microsatellite variations of Plasmodium falciparum Na+/H+ exchanger (Pfnhe-1) gene with reduced in vitro susceptibility to quinine: lack of confirmation in clinical isolates from Africa. , 2010, The American journal of tropical medicine and hygiene.

[56]  P. Rosenthal,et al.  Pharmacokinetics of Artemether-Lumefantrine and Artesunate-Amodiaquine in Children in Kampala, Uganda , 2009, Antimicrobial Agents and Chemotherapy.

[57]  A. Djimde,et al.  Understanding the pharmacokinetics of Coartem® , 2009, Malaria Journal.

[58]  A. Githeko,et al.  Genetic structure of Plasmodium falciparum populations between lowland and highland sites and antimalarial drug resistance in Western Kenya. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[59]  J. Simpson,et al.  Population pharmacokinetics of artesunate and amodiaquine in African children , 2009, Malaria Journal.

[60]  M. F. Boni,et al.  Probability of emergence of antimalarial resistance in different stages of the parasite life cycle , 2009, Evolutionary applications.

[61]  A. Dicko,et al.  Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali , 2009, Malaria Journal.

[62]  D. Wirth,et al.  Selection of Plasmodium falciparum Multidrug Resistance Gene 1 Alleles in Asexual Stages and Gametocytes by Artemether-Lumefantrine in Nigerian Children with Uncomplicated Falciparum Malaria , 2008, Antimicrobial Agents and Chemotherapy.

[63]  A. Ghani,et al.  Modelling the Impact of Artemisinin Combination Therapy and Long-Acting Treatments on Malaria Transmission Intensity , 2008, PLoS medicine.

[64]  O. Rodrigues,et al.  Effect of Concomitant Artesunate Administration and Cytochrome P4502C8 Polymorphisms on the Pharmacokinetics of Amodiaquine in Ghanaian Children with Uncomplicated Malaria , 2008, Antimicrobial Agents and Chemotherapy.

[65]  A. Githeko,et al.  Molecular epidemiology of drug-resistant malaria in western Kenya highlands , 2008, BMC Infectious Diseases.

[66]  A. Dicko,et al.  Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. , 2008, The American journal of tropical medicine and hygiene.

[67]  Abdullah S. Ali,et al.  Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[68]  P. Rosenthal,et al.  Resistance-Mediating Plasmodium falciparum pfcrt and pfmdr1 Alleles after Treatment with Artesunate-Amodiaquine in Uganda , 2007, Antimicrobial Agents and Chemotherapy.

[69]  F. Nosten,et al.  Pharmacokinetic study of artemether–lumefantrine given once daily for the treatment of uncomplicated multidrug‐resistant falciparum malaria , 2007, Tropical medicine & international health : TM & IH.

[70]  A. Björkman,et al.  Amodiaquine resistance is not related to rare findings of pfmdr1 gene amplifications in Kenya , 2006, Tropical medicine & international health : TM & IH.

[71]  N. Maire,et al.  Comparison of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum. , 2006, The American journal of tropical medicine and hygiene.

[72]  P. Rosenthal,et al.  Selection of Plasmodium falciparum pfmdr1 Alleles following Therapy with Artemether-Lumefantrine in an Area of Uganda where Malaria Is Highly Endemic , 2006, Antimicrobial Agents and Chemotherapy.

[73]  P. Rosenthal,et al.  Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria in Uganda , 2006, PLoS clinical trials.

[74]  T. Ishizaki,et al.  The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. , 2005, British journal of clinical pharmacology.

[75]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[76]  E. Linders,et al.  Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. , 2001, Molecular and biochemical parasitology.

[77]  P. Grambsch,et al.  A Package for Survival Analysis in S , 1994 .

[78]  P. Boreham,et al.  The relationship of host size to feeding by mosquitoes of the Anopheles gambiae Giles complex (Diptera: Culicidae) , 1980 .